News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Mochida Pharmaceuticals Completes Early Phase II Clinical Trial Of Epadel Indicated For Alzheimer’s Disease
December 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Tokyo (JCN) Dec 15, 2005 - Mochida Pharmaceutical has completed an early phase II clinical trial of Epadel, which is targeted at Alzheimer's disease. Epadel is the company's proprietary agent used in the treatment of hyperlipemia.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Asia
MORE ON THIS TOPIC
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
April 2, 2026
·
2 min read
·
Nick Paul Taylor
Insights
The Radiotherapeutics Moment: How Isotopes are Changing Cancer Treatment
April 2, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges
April 2, 2026
·
5 min read
·
Angela Gabriel
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
April 1, 2026
·
2 min read
·
Nick Paul Taylor
